RecallRadar

FDA Drug recall D-0213-2024

Eprontia (topiramate) oral solution, 25 mg/mL, 473 mL Bottle, Rx only, Manufactured for: Azurity Pharmaceuticals, Woburn, MA 01801, NDC 526…

On 2024-01-10 the FDA classified a Class III recall of Eprontia (topiramate) oral solution, 25 mg/mL, 473 mL Bottle, Rx only, Manufactured for: Azurity Pharmaceuticals, Woburn, MA 01801, NDC 526… by Azurity Pharmaceuticals, citing failed Impurities/Degradation Specifications: Out of specification Impurity C (4,5-desisopropylidene topiramate) result observed during routine stability testing at 18 months.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0213-2024
ClassificationClass III
Statusterminated
Initiated2023-12-08
Published2024-01-10
Last updated2026-09-13 11:52 UTC
CompanyAzurity Pharmaceuticals
DistributionUS

Product

Eprontia (topiramate) oral solution, 25 mg/mL, 473 mL Bottle, Rx only, Manufactured for: Azurity Pharmaceuticals, Woburn, MA 01801, NDC 52652-9001-1

Reason

Failed Impurities/Degradation Specifications: Out of specification Impurity C (4,5-desisopropylidene topiramate) result observed during routine stability testing at 18 months.

Identifiers

ndc52652-9001-1
ndc52652-9001-2
ndc52652-9001-3
code_infoLot #: MB22020B, Exp 12/27/2023

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0213-2024%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.